source
- Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast CancerCapivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.onclive · 2mo ago↗ source
- FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinomaonclive · 2mo ago↗ source
- UT MD Anderson Shares Latest Research BreakthroughsThe University of Texas MD Anderson Cancer Center released recent oncology research highlights.onclive · 2mo ago↗ source